Medyssey메디쎄이

Medyssey, a small spinal implant maker on KONEX, has no full-year financials in the data and recent news is limited to FDA clearances.

Medyssey designs and sells spinal implants and surgical instruments, exporting to 25 countries with subsidiaries in the US, Mexico and Chile. The shares closed at ₩12,000 on 2026-10-23, with a market cap of ₩44.7B, near the top of their 52-week range of ₩0 to ₩13,000. The data contains no trailing or annual financials, so the current earnings position cannot be assessed from it.

What stands out

• Recent filings include two FDA 510(k) clearances: the OdysSI Screw (2026-10-16) and the NeckTune SA Cervical Cage (2026-10-01), plus an earlier acquisition of a 3D SA cervical cage clearance (2026-06-16).
• Share price is up 14.9% over one month, 8.1% over three months and 5.4% over one year.
• Valuation ratios (P/E, P/B, P/S, EV/EBITDA) are not available because financials are missing, and the dividend yield is 0%.
• Over the last 20 days, retail investors were net sellers of about ₩11.4M, institutions net buyers of about ₩4.8M, and foreign flows were zero; foreign ownership is 1.1%, unchanged over 60 days.
• Peer comparison is limited: peers such as TSE, Kctech, Classys, Park Systems and DI have P/E ratios from 13.2 to 71.9, but Medyssey's own P/E is not available.

What to watch

• Full-year and interim financial results, which are not in the data and would be needed to judge profitability and valuation.
• Further FDA clearances or commercial launches of the newly cleared spinal products, and any effect on sales through distributors and hospitals.
• Insider shareholding reports and the low foreign ownership level, given the thin trading and small market cap.